International Journal of Cell Biology

International Journal of Cell Biology / 2010 / Article
Special Issue

Cell Stress and Cell Death

View this Special Issue

Research Article | Open Access

Volume 2010 |Article ID 818497 |

Katarzyna Mnich, David P. Finn, Eilis Dowd, Adrienne M. Gorman, "Inhibition by Anandamide of 6-Hydroxydopamine-Induced Cell Death in PC12 Cells", International Journal of Cell Biology, vol. 2010, Article ID 818497, 10 pages, 2010.

Inhibition by Anandamide of 6-Hydroxydopamine-Induced Cell Death in PC12 Cells

Academic Editor: Osamu Hori
Received30 Jul 2009
Revised22 Oct 2009
Accepted10 Nov 2009
Published16 Feb 2010


6-hydroxydopamine (6-OHDA) is a selective neurotoxin that is widely used to investigate cell death and protective strategies in models of Parkinson's disease. Here, we investigated the effects of the endogenous cannabinoid, anandamide, on 6-OHDA-induced toxicity in rat adrenal phaeochromocytoma PC12 cells. Morphological analysis and caspase-3 activity assay revealed that anandamide inhibited 6-OHDA-induced apoptosis. The protection was not affected by antagonists of either cannabinoid receptors ( or ) or the vanilloid receptor TRPV1. Anandamide-dependent protection was reduced by pretreatment with LY294002 (inhibitor of phosphatidylinositol 3-kinase, PI3K) and unaffected by U0126 (inhibitor of extracellularly-regulated kinase). Interestingly, phosphorylation of c-Jun-NH2-terminal kinase (JNK) in cells exposed to 6-OHDA was strongly reduced by anandamide pre-treatment. Furthermore, 6-OHDA induced c-Jun activation and increased Bim expression, both of which were inhibited by anandamide. Together, these data demonstrate antiapoptotic effects of anandamide and also suggest a role for activation of PI3K and inhibition of JNK signalling in anandamide-mediated protection against 6-OHDA.

1. Introduction

In recent years, the endogenous cannabinoid (endocannabinoid) system has emerged as a potential therapeutic target for the treatment of Parkinson’s disease [15]. These studies suggest that the potential therapeutic benefits of cannabinoid drugs may include neuroprotection of nigrostriatal dopaminergic neurons. This is of particular interest since neuroprotective therapies for Parkinson’s disease are notably lacking, and current therapies are generally dopamine-enhancing strategies, that neither halt nor delay ongoing neurodegeneration. Anandamide (also known as arachidonylethanolamide), was the first endocannabinoid to be discovered, is derived from arachidonic acid and found principally in brain tissue [6]. Anandamide binds and activates the cannabinoid receptors ( and ) and also the vanilloid receptor, TRPV1 [7, 8].

Mounting evidence supports a role for anandamide in the modulation of cell fate, including cell death and survival. Anandamide can protect neurons from toxic insults such as glutamatergic excitotoxicity, nutrient deprivation, hypoxia and ischemia [912]. These protective effects of anandamide have been reported to be mediated by and cannabinoid receptors, whereas activation of TRPV1 has been suggested to mediate anandamide-induced apoptosis in rat C6 glioma cells, human DAUDI leukemia cells, and cervical carcinoma cell lines [1315].

The present study was undertaken to examine the ability of anandamide to protect PC12 cells against 6-hydroxydopamine (6-OHDA) toxicity. 6-OHDA is a hydroxylated analogue of dopamine that is commonly used in model systems to mimic Parkinson’s disease [16, 17]. 6-OHDA induces apoptosis of primary mesencephalic dopaminergic neurons [18, 19], MN9D [20] and dopaminergic cell lines including PC12 [17, 21, 22]. Apoptosis is a highly regulated form of cell death that occurs under physiological and pathological conditions. It is characterised morphologically by cell shrinkage and nuclear condensation. These changes are mediated by activation of caspase proteases, and in the case of 6-OHDA this occurs as a result of release of cytochrome c from the mitochondria [22].

Here we examine the effect of anandamide on 6-OHDA-induced toxicity in PC12 cells. In particular, the mechanism of anandamide action against 6-OHDA was tested by examining the possible role of signalling pathways, which are well known to be involved in regulation of cell fate, including phoshpatidylinositol 3-kinase (PI3K)/Akt, mitogen activated protein kinase (MAPK)/extracellular signal-regulated kinase1/2 (ERK1/2) and c-Jun-NH2-terminal kinase (JNK)/c-Jun pathways.

2. Experimental Procedures

2.1. Materials

Rat phaeochromocytoma PC12 cells were obtained from European Collection of Cell Cultures (ECACC). All chemicals were supplied by Sigma–Aldrich unless stated otherwise. Anandamide and SB366791 were obtained from Tocris Bioscience. SR141716A and SR144528 were from NIMH Chemical Synthesis and Drug Supply Program. U0126 and SP600125 were supplied by Calbiochem. Rabbit polyclonal antibody against Bim was from StressGen Biotechnologies. Mouse monoclonal antibody against p-JNK, rabbit polyclonal anti-caspase-3 antibody and rabbit monoclonal antibody against p-ERK1/2 were obtained from Cell Signalling Technology. Mouse monoclonal antibody against p-c-Jun was from Santa Cruz Biotechnology. Anti-Actin rabbit polyclonal antibody was from Sigma-Aldrich. Goat secondary antibodies conjugated to horseradish peroxidase were from Pierce. Ac-Asp-Glu-Val-Asp-a-(4-methyl-coumaryl-7-amide) (DEVD-MCA) was from the Peptide Institute, Osaka, Japan. Protein molecular weight marker was obtained from New England Biolabs.

2.2. Cell Culture and Treatments

Rat adrenal phaeochromocytoma PC12 cells were cultured in DMEM supplemented with 10% horse serum, 5% fetal calf serum, 50 U/ml penicillin and 50 μg/ml streptomycin, at C in a humidified atmosphere. For experiments, cells were seeded at a density of cells/cm2 in plates coated with 10 μg/ml poly-L-lysine. Cells were left overnight before commencing experimental treatments. Stock solutions of 6-OHDA were made freshly in sodium metabisulfite (1 M) prior to each experiment. Unless otherwise stated, PC12 cells were incubated with 25  M anandamide for 24 hours followed by treatment with 100  M 6-OHDA for further 24 hours before analysis.

2.3. Cell Viability and Proliferation Assay

Cell survival was determined by using colorimetric MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazoliumbromide) tetrazolium salt assay [23]. PC12 cells were plated into 96-well plates at cells/well in 100  l of medium. MTT tetrazolium salt was dissolved in Hank’s balanced salt solution to concentration of 5 mg/ml. After experimental treatments, 10  l of MTT was added to the culture for 3 hours at C. To stop the reaction and solubilize the formazan crystals 100  l of 20% SDS in 50% dimethyl formamide was added and the absorbance was measured at 550 nm by a Wallac 1420 plate-reader with a reference wavelength of 650 nm. Cell viability was expressed as percent of the control culture.

2.4. DAPI Staining of Nuclei

Cells were washed in PBS and fixed with 3.7% paraformaldehyde for 10 minutes at room temperature. Nuclei were stained with -6-diamidino-2-phenylindole (DAPI) and placed in mounting medium (Vectashield, Vector, Burlingame, CA). 5  l aliquot of the cell suspensions were applied to glass slides. Morphological changes in chromatin of cells undergoing apoptosis were analysed by fluorescence microscopy (excitation 350 nm and emission at 460 nm). Cells were scored by counting at least 300 cells from each sample.

2.5. DEVDase Activity Assay

The activity of caspase-3-like enzymes (DEVDases) was determined fluorometrically as reported previously [24] with some modifications [22, 25]. Briefly, cells were scraped and spun down at at C for 5 min. Pellets were washed in ice-cold phosphate-buffered saline (PBS) and spun down again at for 10 seconds. The pellets were re-suspended in 25  l PBS and snap-frozen in liquid nitrogen. 50  M of DEVDase-substrate (DEVD-MCA) in reaction buffer (100 mM N-2-hydroxyethyl-piperazine-N-2-ethanesulphonic acid (HEPES) pH 7.5, 10% sucrose, 0.1% 3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate (CHAPS), 5 mM dithiothreitol (DTT), % Nonidet-P-40) was added into lysates and the release of free AMC was monitored at C at 60 seconds intervals over a 30 minute period using a Wallac Victor multilabel counter (excitation 355 nm, emission 460 nm). Fluorescent units were converted to nanomoles of AMC released using a standard curve generated with free AMC and subsequently related to protein concentration.

2.6. Preparation of Whole Cell Extracts

Following experimental treatments cells were scraped from the culture flasks and centrifuged at for 5 minutes at C. After washing in PBS cells were lysed using whole cell lysis buffer (20 mM HEPES pH 7.5, 350 mM NaCl, 1 mM , 0.5 mM EDTA, 0.1 mM EGTA, 1% Nonidet P-40, 0.5 mM DTT, 0.1% phenylmethylsulphonyl fluoride (PMSF), 1% aprotinin, 5 mM NaF, and 1 mM ). Cellular debris was spun down at for 1 minute and supernatant was taken to determine the protein content using Bradford reagent with bovine serum albumin (BSA) as the standard.

2.7. Western Blotting

40  g of proteins were denatured using Laemmli’s sample buffer (62 mM Tris-HCl, pH 6.8, 2% sodium dodecyl sulphate (SDS), 5% -mercaptoethanol, 4% glycerol, 1 mM PMSF, 0.01% bromophenol blue) and boiled at C for 5 minutes. Proteins were separated by 10%–15% SDS-PAGE and electrophoretically transferred onto nitrocellulose membranes. Membranes were blocked for 1 hour in PBS containing 0.05% Tween 20 and 5% (w/v) non-fat dried milk. Membranes were probed with antibodies (1  :  1000) overnight at C followed by appropriate horseradish peroxidise-conjugated goat secondary antibody at 1  :  10,000 (or 1  :  2,000 for detection of caspase-3) for 2 hours at room temperature. Protein bands were visualized using Supersignal West pico system (Pierce).

2.8. Statistical Analysis

Values are expressed as means ± SEM of 3 separate experiments unless otherwise indicated. Statistical analysis was performed using repeated-measures ANOVA followed by Bonferroni multiple comparisons post hoc test, for which levels of were considered to be significant.

3. Results

3.1. Anandamide Pre-Treatment Protects PC12 Cells against 6-OHDA Toxicity

We have previously shown that 6-OHDA causes a concentration-dependent induction of apoptosis in PC12 cells [22]. In order to examine the effect of anandamide against 6-OHDA, PC12 cells were incubated with 25  M anandamide for 24 hour followed by exposure to 100  M 6-OHDA for a further 24 hours. Visualisation of nuclear morphology by DAPI staining demonstrated that pre-treatment of PC12 cells with anandamide inhibited 6-OHDA-induced apoptosis (Figure 1(a)). The level of cell death due to 6-OHDA with and without prior anandamide treatment was quantified and expressed as a percentage of the total number of cells. Anandamide alleviated the morphological manifestation of cell damage and reduced cell death from to (Figure 1(b)).

Next the effect of anandamide on caspase 3-like activity (DEVD-MCA cleavage activity) was examined. PC12 cells were treated with 0–50  M anandamide for 24 hours prior to treatment with 6-OHDA for a further 24 hours. Anandamide effectively inhibited DEVD-MCA-cleavage activity in a concentration-dependent manner, causing approximately 50% inhibition at 10  M anandamide (Figure 1(c)). This was accompanied by a reduction in the processing of pro-caspase-3 into its active 17 kDa form, as detected by Western blotting (Figure 1(d)). These data indicate that anandamide can protect against 6-OHDA-induced apoptosis at the level of, or upstream of, caspase-3 activation.

3.2. Anandamide-Mediated Protection Is Cannabinoid and Vanilloid Receptor-Independent

In order to determine whether the effect of anandamide is receptor-mediated, PC12 cells, which express the receptor ( [26], and our own data not shown) were incubated with selective or receptor antagonists, SR141716A or SR144528, respectively, prior to treatment with 25  M anandamide and 6-OHDA. The receptor antagonists did not inhibit the protective effects of anandamide, indicating that neither nor receptors are involved in anandamide protection against 6-OHDA toxicity (Figures 2(a) and 2(b)). Application of the antagonists at excess concentrations (25  M for SR141716A; 20  M for SR144528) also did not reverse the protection (Figures 2(a) and 2(b)). Since anandamide also has activity at the TRPV1 vanilloid receptor [8], and since this receptor is expressed in PC12 cells [26, 27], the effect of a TRPV1 selective antagonist, SB366791, on anandamide protection was examined. SB366791 had no effect on the protective abilities of anandamide against 6-OHDA-induced caspase activity (Figure 2(c)). In addition, none of the antagonists had any effect on 6-OHDA-induced DEVDase activity in the absence of anandamide. Cannabinoids, particularly those possessing a phenolic ring, are known to exert receptor-independent effects on cells and the neuroprotective effects have been suggested to be related to the potent antioxidant properties of cannabinoids [28]. Since 6-OHDA-induced cell death can be mediated by oxidative stress [17, 20, 29], the effect of anandamide on -induced cell death was examined. Anandamide did not prevent cell death due to as determined by MTT survival assay (Figure 3). This suggests that anandamide-mediated protection against 6-OHDA is not a consequence of its antioxidant ability.

3.3. Involvement of PI3K and ERK1/2 Signalling Pathways in the Prosurvival Action of Anandamide

Cannabinoid-dependent effects have been associated with several signal transduction pathways including activation of phosphatidylinositol 3-kinase (PI3K)/Akt and mitogen-activated protein kinase (MAPK) signalling pathways, both of which are linked to prosurvival signalling [3032]. To gain insight into the molecular mechanism leading to cell survival, we studied the role of these signalling pathways in anandamide protection. Inhibition of PI3K with 40  M LY294002 was found to exacerbate 6-OHDA toxicity (Figure 4(a)). Pre-treatment with LY294002 reversed anandamide-mediated protection, although not to the level in the absence of anandamide, probably due to the effect of LY294002 in enhancing 6-OHDA-induced toxicity.

To assess a possible role of MEK/ERK signalling in anandamide-mediated protection, we used Western blotting to examine the effect of anandamide on the phosphorylation status of ERK1/2. Treatment of PC12 cells with 25  M anandamide resulted in a transient increase in ERK1/2 phosphorylation at 6 hours that returned to basal levels by 24 hours (Figure 4(b)). Pharmacological inhibition of ERK activation by 10  M U0126 partially reversed the effect of anandamide on DEVDase activity, but without statistical significance (Figure 4(c)). This suggests that the increase in ERK1/2 phosphorylation does not make a major contribution to anandamide-mediated protection.

3.4. Anandamide Inhibits JNK Activation Induced by 6-OHDA

The stress kinase JNK has been reported to mediate 6-OHDA-induced cell death [20, 33]. Therefore, we examined the effect of anandamide on JNK activation by examining the phosphorylation status of JNK1 and JNK2. Treatment of PC12 cells with 100  M 6-OHDA evoked a time-dependent increase in JNK1 phosphorylation with maximal activation after 6 hours (Figure 5(a)). There was a smaller increase in JNK2 phosphorylation that followed the same time course. Prior treatment with anandamide resulted in a marked inhibition of JNK1 phosphorylation (Figure 5(a)). These findings suggest that suppression of JNK activation may play an important role in anandamide-dependent protection against 6-OHDA and are in agreement with other studies showing that inhibition of JNK activity protects PC12 cells against 6-OHDA-induced apoptosis [20, 3337].

Many JNK targets are implicated in cell death, including c-Jun and the BH3-only protein Bim [38]. Therefore, the effect of anandamide on these JNK targets was examined. 6-OHDA caused an increase in c-Jun phosphorylation which was reduced by anandamide pre-treatment (Figure 5(b)). , a pro-apoptotic member of the Bcl-2 family, is also a target of JNK. Treatment of cells with 6-OHDA caused a marked increase in expression by 12 hours (Figure 5(b)). Three bands were observed with the higher molecular weight forms probably reflecting phosphorylated species, since this protein is known to be regulated by phosphorylation [39, 40]. In fact, we have previously shown that these upper bands represent phosphorylated , since they disappear upon treatment of whole cell lysates with phosphatase [32]. Pre-treatment of the cells with anandamide did not appear to affect the time course or level of induction of (Figure 5(b)). However, there was a reduction in the higher molecular weight band for and an increase in the intensity of the lower molecular weight band at 24 hours of 6-OHDA with AEA treatment (Figure 5(b)). These data suggest that there is an anandamide-induced reduction in phosphorylation of , possibly due to JNK inhibition.

In order to confirm a role for JNK activation in 6-OHDA toxicity, cells were pre-treated with the JNK inhibitor SP600125 (4  M). This inhibitor reduced phosphorylation of c-Jun by 6-OHDA and also caused a delay and a reduction in cleavage of caspase-3 to its active p17 fragment (Figure 5(c)). In the same experiment, 25  M anandamide had caused complete inhibition of caspase-3 cleavage while inhibiting c-Jun phosphorylation, but to a lesser extent than SP600125.

4. Discussion

Here we provide the first evidence for direct protective effects of anandamide against 6-OHDA toxicity. Anandamide blocks 6-OHDA-induced apoptosis in a concentration-dependent manner. This protection was upstream of caspase-3 activation since there was inhibition of DEVDase activity and a reduction in processing of pro-caspase-3. We were unable to demonstrate a role for , or TRPV1 in anandamide protection. Nor did it involve ERK1/2 prosurvival signalling. However, a partial role for PI3K activation and suppression of JNK signalling were demonstrated. Cannabinoids have been shown to both induce and inhibit induction of cell death, (reviewed by [41]). Anandamide itself has been reported to be toxic [26] or nontoxic [42] to PC12 cells. In our study, anandamide, at the concentrations used, was not toxic even up to 48 hours of incubation (data not shown). Cannabinoid drugs have been shown by others to be protective in a variety of models of neurodegeneration [9, 41, 43], including neuronal cell death in models of Parkinson’s disease [28]. For example, the non-selective synthetic cannabinoid receptor agonist HU210 was found to protect cerebellar granule neurons against 6-hydroxydopamine toxicity [28]. Furthermore, an in vivo study demonstrated that the plant-derived cannabinoids -THC and cannabidiol protect the rat nigrostriatal dopaminergic pathway from a medial forebrain bundle injection of the catecholamine neurotoxin 6-hydroxydopamine [28]. Although that in vivo study did not include direct assessment of neuroprotection, the ability of -THC or cannabidiol to ameliorate the effects of the 6-OHDA lesion on striatal dopamine concentration and tyrosine hydroxylase activity were shown. Our current data with anandamide support these earlier findings.

A possible role of metabolites of anandamide in the regulation of PC12 cell fate cannot be ruled out. Anandamide is enzymatically hydrolysed to ethanolamine and arachidonic acid [44]. In fact, this degradation has been shown to be necessary for its prosurvival effects in murine neuroblastoma cells where anandamide protective activity against serum deprivation was not mediated via or TRPV1 receptors and required a breakdown of anandamide to ethanolamine [9].

It has been reported that induction of oxidative stress is involved in 6-OHDA-induced toxicity and antioxidants can protect against hydrogen peroxide and superoxide anion-mediated cell death [20, 3337, 4547]. To our knowledge, anandamide has not been reported to possess antioxidant activity. We did not observe anandamide-mediated protection of PC12 cells against -induced death, suggesting that anandamide does not inhibit oxidative stress due to 6-OHDA. However, H2O2 is not the only product of 6-OHDA auto-oxidation. In addition, superoxide anions and p-quinone, may contribute to reactive oxygen species (ROS) production [4850] and may be inhibited by anandamide, thus blocking JNK activation and phosphorylation of its downstream targets.

Cannabinoids have been shown to activate PI3K/Akt and MEK/ERK signalling pathways [51, 52]. While our results obtained with pharmacological inhibitors did not support a role for MEK/ERK signalling in anandamide protection against 6-hydroxydopamine, they did support an involvement of PI3K/Akt prosurvival signalling, since the PI3K selective inhibitor LY294002 reversed anandamide protection against 6-OHDA. In addition, the present data also support a possible role for inhibition of JNK activation in anandamide protection, since anandamide reduced 6-OHDA-induced JNK phosphorylation and JNK-dependent pro-apoptotic signalling, namely phosphorylation of c-Jun and possibly of .

JNKs are members of the mitogen-activated protein kinase (MAPK) pathway that is activated in response to many extracellular stimuli and different forms of environmental stress [53]. Our findings are in general agreement with recent reports showing that 6-OHDA induces JNK phosphorylation [36, 54] and that JNK activation mediates apoptosis induced by 6-OHDA in PC12 cells [45, 47, 54]. Furthermore, a number of studies showing protection by various agents against 6-OHDA neurotoxicity also show a concomitant suppression of JNK activation [20, 3337]. We observed a large 6-OHDA-induced increase in phosphorylation of JNK1, and a minor increase in levels of phosphorylated JNK2 at 3–6 hours, which are accompanied by a concomitant increase in phospho-c-Jun and a delayed increase in the levels of . Furthermore, the JNK inhibitor SP600125 caused a partial reduction in caspase-3 cleavage due to 6-OHDA. This was in contrast to complete inhibition by anandamide. These findings are in agreement with a previous report showing that SP600125 partially protects against 6-OHDA toxicity in PC12 cells [47]. Taken together, these data suggest a partial contribution of JNK signalling in the toxicity of 6-OHDA, and that anandamide may mediate some of its protective effect through suppression of this pathway.

JNK promotes apoptosis in a number of ways. Through phosphorylation and activation of c-Jun it stimulates the transcription of c-Jun target genes, including Bim [38]. In addition, JNK phosphorylates certain members of the Bcl-2 protein family, associated with the mitochondrial apoptotic pathway, including , Bmf, and Bcl-2 [38, 53]. For example, levels and function are regulated by phosphorylation by ERK, JNK and possibly Akt [40, 55]. Phosphorylation of at Ser65 by active JNK potentiates its pro-apoptotic activity [56]. These data support an attractive hypothesis that anandamide protects against 6-OHDA at the level of, or upstream of, JNK activation. This inhibition of JNK by anandamide thus prevents the activation of downstream apoptotic pathways, including activation of c-Jun and possibly phosphorylation of . However, since the level of cytoprotection by anandamide was far greater than that due to SP600125, despite similar JNK inhibition, it strongly suggests that anandamide utilises additional mechanisms to inhibit 6-OHDA toxicity.

It should be considered that in contrast to the data supporting endocannabinoid-mediated JNK inhibition, there are data reported by others [5759] indicating that cannabinoids induce JNK activation, an effect that precedes apoptotic events including caspase-3 activation and DNA fragmentation. Thus, the neuroprotective and neurotoxic effects of cannabinoids are likely to depend on a variety of factors, including toxic insults, doses and nature of cannabinoids (e.g., endocannabinoids versus phytocannabinoids), times of exposure and cell type [60, 61].

Here, for the first time we demonstrate that anandamide protects PC12 cells against 6-OHDA-induced apoptosis. These data and those of other studies may suggest potential therapeutic benefits of elevating anandamide and possibly other endocannabinoids in preventing the degeneration of nigrostriatal dopaminergic neurons in Parkinson's disease.


The authors would like to thank Prof Ken Mackie for kindly providing us with receptor antibody. This work was financially supported by the Irish Research Council for Science, Engineering and Technology (an EMBARK scholarship to KM) and by Science Foundation Ireland.


  1. J. Ševčík and K. Mašek, “Potential role of cannabinoids in Parkinson's disease,” Drugs and Aging, vol. 16, no. 6, pp. 391–395, 2000. View at: Google Scholar
  2. J. Romero, I. Lastres-Becker, R. de Miguel, F. Berrendero, J. A. Ramos, and J. Fernández-Ruiz, “The endogenous cannabinoid system and the basal ganglia: biochemical, pharmacological, and therapeutic aspects,” Pharmacology and Therapeutics, vol. 95, no. 2, pp. 137–152, 2002. View at: Publisher Site | Google Scholar
  3. J. M. Brotchie, “CB1 cannabinoid receptor signalling in Parkinson's disease,” Current Opinion in Pharmacology, vol. 3, no. 1, pp. 54–61, 2003. View at: Publisher Site | Google Scholar
  4. J. Fernández-Ruiz, J. Romero, G. Velasco, R. M. Tolón, J. A. Ramos, and M. Guzmán, “Cannabinoid CB2 receptor: a new target for controlling neural cell survival?” Trends in Pharmacological Sciences, vol. 28, no. 1, pp. 39–45, 2007. View at: Publisher Site | Google Scholar
  5. M. Jimenez-Del-Rio, A. Daza-Restrepo, and C. Velez-Pardo, “The cannabinoid CP55,940 prolongs survival and improves locomotor activity in Drosophila melanogaster against paraquat: implications in Parkinson's disease,” Neuroscience Research, vol. 61, no. 4, pp. 404–411, 2008. View at: Publisher Site | Google Scholar
  6. W. A. Devane, L. Hanus, A. Breuer et al., “Isolation and structure of a brain constituent that binds to the cannabinoid receptor,” Science, vol. 258, no. 5090, pp. 1946–1949, 1992. View at: Google Scholar
  7. E. Fride and R. Mechoulam, “Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent,” European Journal of Pharmacology, vol. 231, no. 2, pp. 313–314, 1993. View at: Publisher Site | Google Scholar
  8. D. Smart, M. J. Gunthorpe, J. C. Jerman et al., “The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1),” British Journal of Pharmacology, vol. 129, no. 2, pp. 227–230, 2000. View at: Google Scholar
  9. D. Matas, A. Juknat, M. Pietr, Y. Klin, and Z. Vogel, “Anandamide protects from low serum-induced apoptosis via its degradation to ethanolamine,” Journal of Biological Chemistry, vol. 282, no. 11, pp. 7885–7892, 2007. View at: Publisher Site | Google Scholar
  10. B. Shouman, R. H. Fontaine, O. Baud et al., “Endocannabinoids potently protect the newborn brain against AMPA-kainate receptor-mediated excitotoxic damage,” British Journal of Pharmacology, vol. 148, no. 4, pp. 442–451, 2006. View at: Publisher Site | Google Scholar
  11. A. D. Sinor, S. M. Irvin, and D. A. Greenberg, “Endocannabinoids protect cerebral cortical neurons from in vitro ischemia in rats,” Neuroscience Letters, vol. 278, no. 3, pp. 157–160, 2000. View at: Publisher Site | Google Scholar
  12. M. Schomacher, H. D. Müller, C. Sommer, S. Schwab, and W.-R. Schäbitz, “Endocannabinoids mediate neuroprotection after transient focal cerebral ischemia,” Brain Research, vol. 1240, pp. 213–220, 2008. View at: Publisher Site | Google Scholar
  13. E. Contassot, R. Wilmotte, M. Tenan et al., “Arachidonylethanolamide induces apoptosis of human glioma cells through vanilloid receptor-1,” Journal of Neuropathology and Experimental Neurology, vol. 63, no. 9, pp. 956–963, 2004. View at: Google Scholar
  14. M. Maccarrone, T. Lorenzon, M. Bari, G. Melino, and A. Finazzi-Agro, “Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors,” Journal of Biological Chemistry, vol. 275, no. 41, pp. 31938–31945, 2000. View at: Google Scholar
  15. W. B. Veldhuis, M. van der Stelt, M. W. Wadman et al., “Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vivo excitotoxicity in the rat: role of vanilloid receptors and lipoxygenases,” Journal of Neuroscience, vol. 23, no. 10, pp. 4127–4133, 2003. View at: Google Scholar
  16. H. Thoenen and J. P. Tranzer, “Chemical sympathectomy by selective destruction of adrenergic nerve endings with 6-hydroxydopamine,” Naunyn-Schmiedebergs Archiv für Pharmakologie und Experimentelle Pathologie, vol. 261, no. 3, pp. 271–288, 1968. View at: Publisher Site | Google Scholar
  17. D. Blum, S. Torch, N. Lambeng et al., “Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease,” Progress in Neurobiology, vol. 65, no. 2, pp. 135–172, 2001. View at: Publisher Site | Google Scholar
  18. J. Lotharius, L. L. Dugan, and K. L. O'Malley, “Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons,” Journal of Neuroscience, vol. 19, no. 4, pp. 1284–1293, 1999. View at: Google Scholar
  19. B. S. Han, H.-S. Hong, W.-S. Choi, G. J. Markelonis, T. H. Oh, and Y. J. Oh, “Caspase-dependent and -independent cell death pathways in primary cultures of mesencephalic dopaminergic neurons after neurotoxin treatment,” Journal of Neuroscience, vol. 23, no. 12, pp. 5069–5078, 2003. View at: Google Scholar
  20. W.-S. Choi, S.-Y. Yoon, T. H. Oh, E.-J. Choi, K. L. O'Malley, and Y. J. Oh, “Two distinct mechanisms are involved in 6-hydroxydopamine- and MPP+-induced dopaminergic neuronal cell death: role of caspases, ROS, and JNK,” Journal of Neuroscience Research, vol. 57, no. 1, pp. 86–94, 1999. View at: Publisher Site | Google Scholar
  21. G. Walkinshaw and C. M. Waters, “Neurotoxin-induced cell death in neuronal PC12 cells is mediated by induction of apoptosis,” Neuroscience, vol. 63, no. 4, pp. 975–987, 1994. View at: Publisher Site | Google Scholar
  22. A. M. Gorman, E. Szegezdi, D. J. Quigney, and A. Samali, “Hsp27 inhibits 6-hydroxydopamine-induced cytochrome c release and apoptosis in PC12 cells,” Biochemical and Biophysical Research Communications, vol. 327, no. 3, pp. 801–810, 2005. View at: Publisher Site | Google Scholar
  23. T. Mosmann, “Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays,” Journal of Immunological Methods, vol. 65, no. 1-2, pp. 55–63, 1983. View at: Google Scholar
  24. D. W. Nicholson, A. Ali, N. A. Thornberry et al., “Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis,” Nature, vol. 376, no. 6535, pp. 37–43, 1995. View at: Google Scholar
  25. A. M. Gorman, U. A. Hirt, B. Zhivotovsky, S. Orrenius, and S. Ceccatelli, “Application of a fluorometric assay to detect caspase activity in thymus tissue undergoing apoptosis in vivo,” Journal of Immunological Methods, vol. 226, no. 1-2, pp. 43–48, 1999. View at: Publisher Site | Google Scholar
  26. K. P. Sarker and I. Maruyama, “Anandamide induces cell death independently of cannabinoid receptors or vanilloid receptor 1: possible involvement of lipid rafts,” Cellular and Molecular Life Sciences, vol. 60, no. 6, pp. 1200–1208, 2003. View at: Google Scholar
  27. A. Someya, K. Kunieda, N. Akiyama, T. Hirabayashi, S. Horie, and T. Murayama, “Expression of vanilloid VR1 receptor in PC12 cells,” Neurochemistry International, vol. 45, no. 7, pp. 1005–1010, 2004. View at: Publisher Site | Google Scholar
  28. I. Lastres-Becker, F. Molina-Holgado, J. A. Ramos, R. Mechoulam, and J. Fernández-Ruiz, “Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease,” Neurobiology of Disease, vol. 19, no. 1-2, pp. 96–107, 2005. View at: Publisher Site | Google Scholar
  29. Y. Glinka, M. Gassen, and M. B. H. Youdim, “Mechanism of 6-hydroxydopamine neurotoxicity,” Journal of Neural Transmission, Supplement, vol. 50, pp. 55–66, 1997. View at: Google Scholar
  30. J. E. Cavanaugh, J. D. Jaumotte, J. M. Lakoski, and M. J. Zigmond, “Neuroprotective role of ERK1/2 and ERK5 in a dopaminergic cell line under basal conditions and in response to oxidative stress,” Journal of Neuroscience Research, vol. 84, no. 6, pp. 1367–1375, 2006. View at: Publisher Site | Google Scholar
  31. Z. Lu and S. Xu, “ERK1/2 MAP kinases in cell survival and apoptosis,” IUBMB Life, vol. 58, no. 11, pp. 621–631, 2006. View at: Publisher Site | Google Scholar
  32. E. Szegezdi, K. Reed Herbert, E. T. Kavanagh, A. Samali, and A. M. Gorman, “Nerve growth factor blocks thapsigargin-induced apoptosis at the level of the mitochondrion viaregulation of Bim,” Journal of Cellular and Molecular Medicine, vol. 12, no. 6A, pp. 2482–2496, 2008. View at: Publisher Site | Google Scholar
  33. S. Eminel, A. Klettnert, L. Roemer, T. Herdegen, and V. Waetzig, “JNK2 translocates to the mitochondria and mediates cytochrome c release in PC12 cells in response to 6-hydroxydopamine,” Journal of Biological Chemistry, vol. 279, no. 53, pp. 55385–55392, 2004. View at: Publisher Site | Google Scholar
  34. B. Chetsawang, P. Govitrapong, and M. Ebadi, “The neuroprotective effect of melatonin against the induction of c-Jun phosphorylation by 6-hydroxydopamine on SK-N-SH cells,” Neuroscience Letters, vol. 371, no. 2-3, pp. 205–208, 2004. View at: Publisher Site | Google Scholar
  35. H. J. Lee, Y. H. Noh, D. Y. Lee et al., “Baicalein attenuates 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells,” European Journal of Cell Biology, vol. 84, no. 11, pp. 897–905, 2005. View at: Publisher Site | Google Scholar
  36. L.-L. Tian, Z. Zhou, Q. Zhang et al., “Protective effect of (±) isoborneol against 6-OHDA-induced apoptosis in SH-SY5Y cells,” Cellular Physiology and Biochemistry, vol. 20, no. 6, pp. 1019–1032, 2007. View at: Publisher Site | Google Scholar
  37. J. Chao, M.-S. Yu, Y.-S. Ho, M. Wang, and R. C.-C. Chang, “Dietary oxyresveratrol prevents parkinsonian mimetic 6-hydroxydopamine neurotoxicity,” Free Radical Biology and Medicine, vol. 45, no. 7, pp. 1019–1026, 2008. View at: Publisher Site | Google Scholar
  38. M. A. Bogoyevitch and B. Kobe, “Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases,” Microbiology and Molecular Biology Reviews, vol. 70, no. 4, pp. 1061–1095, 2006. View at: Publisher Site | Google Scholar
  39. S. C. Biswas and L. A. Greene, “Nerve growth factor (NGF) down-regulates the Bcl-2 homology 3 (BH3) domain-only protein Bim and suppresses its proapoptotic activity by phosphorylation,” Journal of Biological Chemistry, vol. 277, no. 51, pp. 49511–49516, 2002. View at: Publisher Site | Google Scholar
  40. E. B. E. Becker, J. Howell, Y. Kodama, P. A. Barker, and A. Bonni, “Characterization of the c-Jun N-terminal kinase-BimEL signaling pathway in neuronal apoptosis,” Journal of Neuroscience, vol. 24, no. 40, pp. 8762–8770, 2004. View at: Publisher Site | Google Scholar
  41. M. Guzmán, C. Sánchez, and I. Galve-Roperh, “Control of the cell survival/death decision by cannabinoids,” Journal of Molecular Medicine, vol. 78, no. 11, pp. 613–625, 2001. View at: Publisher Site | Google Scholar
  42. D. Rueda, B. Navarro, A. Martínez-Serrano, M. Guzmán, and I. Galve-Roperh, “The endocannabinoid anandamide inhibits neuronal progenitor cell differentiation through attenuation of the Rap1/B-Raf/ERK pathway,” Journal of Biological Chemistry, vol. 277, no. 48, pp. 46645–46650, 2002. View at: Publisher Site | Google Scholar
  43. R. Mechoulam, D. Panikashvili, and E. Shohami, “Cannabinoids and brain injury: therapeutic implications,” Trends in Molecular Medicine, vol. 8, no. 2, pp. 58–61, 2002. View at: Publisher Site | Google Scholar
  44. B. F. Cravatt, D. K. Giang, S. P. Mayfield, D. L. Boger, R. A. Lerner, and N. B. Gilula, “Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides,” Nature, vol. 384, no. 6604, pp. 83–87, 1996. View at: Publisher Site | Google Scholar
  45. M. Ouyang and X. Shen, “Critical role of ASK1 in the 6-hydroxydopamine-induced apoptosis in human neuroblastoma SH-SY5Y cells,” Journal of Neurochemistry, vol. 97, no. 1, pp. 234–244, 2006. View at: Publisher Site | Google Scholar
  46. M. Wilhelm, Z. Xu, N. V. Kukekov, S. Gire, and L. A. Greene, “Proapoptotic nix activates the JNK pathway by interacting with POSH and mediates death in a Parkinson disease model,” Journal of Biological Chemistry, vol. 282, no. 2, pp. 1288–1295, 2007. View at: Publisher Site | Google Scholar
  47. J. Rodriguez-Blanco, V. Martín, F. Herrera, G. García-Santos, I. Antolín, and C. Rodriguez, “Intracellular signaling pathways involved in post-mitotic dopaminergic PC12 cell death induced by 6-hydroxydopamine,” Journal of Neurochemistry, vol. 107, no. 1, pp. 127–140, 2008. View at: Publisher Site | Google Scholar
  48. G. Cohen and R. E. Heikkila, “The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6 hydroxydopamine, dialuric acid, and related cytotoxic agents,” Journal of Biological Chemistry, vol. 249, no. 8, pp. 2447–2452, 1974. View at: Google Scholar
  49. Y. Izumi, H. Sawada, N. Sakka et al., “p-quinone mediates 6-hydroxydopamine-induced dopaminergic neuronal death and ferrous iron accelerates the conversion of p-quinone into melanin extracellularly,” Journal of Neuroscience Research, vol. 79, no. 6, pp. 849–860, 2005. View at: Publisher Site | Google Scholar
  50. Y. Saito, K. Nishio, Y. Ogawa et al., “Molecular mechanisms of 6-hydroxydopamine-induced cytotoxicity in PC12 cells: involvement of hydrogen peroxide-dependent and -independent action,” Free Radical Biology and Medicine, vol. 42, no. 5, pp. 675–685, 2007. View at: Publisher Site | Google Scholar
  51. M. Bouaboula, C. Poinot-Chazel, B. Bourrié et al., “Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1,” Biochemical Journal, vol. 312, part 2, pp. 637–641, 1995. View at: Google Scholar
  52. M. G. Sánchez, L. Ruiz-Llorente, A. M. Sánchez, and I. Díaz-Laviada, “Activation of phosphoinositide 3-kinase/PKB pathway by CB1 and CB2 cannabinoid receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction,” Cellular Signalling, vol. 15, no. 9, pp. 851–859, 2003. View at: Publisher Site | Google Scholar
  53. D. N. Dhanasekaran and E. P. Reddy, “JNK signaling in apoptosis,” Oncogene, vol. 27, no. 48, pp. 6245–6251, 2008. View at: Publisher Site | Google Scholar
  54. S. Eminel, L. Roemer, V. Waetzig, and T. Herdegen, “c-Jun N-terminal kinases trigger both degeneration and neurite outgrowth in primary hippocampal and cortical neurons,” Journal of Neurochemistry, vol. 104, no. 4, pp. 957–969, 2008. View at: Publisher Site | Google Scholar
  55. X.-J. Qi, G. M. Wildey, and P. H. Howe, “Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function,” Journal of Biological Chemistry, vol. 281, no. 2, pp. 813–823, 2006. View at: Publisher Site | Google Scholar
  56. G. V. Putcha, S. Le, S. Frank et al., “JNK-mediated BIM phosphorylation potentiates BAX-dependent apoptosis,” Neuron, vol. 38, no. 6, pp. 899–914, 2003. View at: Publisher Site | Google Scholar
  57. D. Rueda, I. Galve-Roperh, A. Haro, and M. Guzman, “The CB1 cannabinoid receptor is coupled to the activation of c-jun N-terminal kinase,” Molecular Pharmacology, vol. 58, no. 4, pp. 814–820, 2000. View at: Google Scholar
  58. E. J. Downer, M. P. Fogarty, and V. A. Campbell, “Tetrahydrocannabinol-induced neurotoxicity depends on CB1 receptor-mediated c-Jun N-terminal kinase activation in cultured cortical neurons,” British Journal of Pharmacology, vol. 140, no. 3, pp. 547–557, 2003. View at: Publisher Site | Google Scholar
  59. K. P. Sarker, K. K. Biswas, M. Yamakuchi et al., “ASK1-p38 MAPK/JNK signaling cascade mediates anandamide-induced PC12 cell death,” Journal of Neurochemistry, vol. 85, no. 1, pp. 50–61, 2003. View at: Google Scholar
  60. L. Ruiz, A. Miguel, and I. Díaz-Laviada, “Δ9-tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism,” FEBS Letters, vol. 458, no. 3, pp. 400–404, 1999. View at: Publisher Site | Google Scholar
  61. L. Velasco, L. Ruiz, M. G. Sánchez, and I. Díaz-Laviada, “Δ9-tetrahydrocannabinol increases nerve growth factor production by prostate PC-3 cells: involvement of CB1 cannabinoid receptor and Raf-1,” European Journal of Biochemistry, vol. 268, no. 3, pp. 531–535, 2001. View at: Publisher Site | Google Scholar

Copyright © 2010 Katarzyna Mnich et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.